Revenue: As of FY2025 Q3, the actual value is USD 3.548 M.EPS: As of FY2025 Q3, the actual value is USD -0.29.EBIT: As of FY2025 Q3, the actual value is USD 74.4 K.<h3>Healthcare Segment</h3><ul><li>Net Revenues: $3.5 million for the three months ended September 30, 2025, compared to $1.2 million for the same period in 2024, an increase of $2.3 million. This includes $0.5 million from the State of Tennessee’s Hospital Improvement Plan (THIP).</li><li>Operating Expenses: $4.3 million for the three months ended September 30, 2025, compared to $1.2 million for the same period in 2024, an increase of $3.0 million.</li><li>Segment Loss: $0.8 million for the three months ended September 30, 2025, compared to $47,698 for the same period in 2024, an increase of $0.7 million.</li></ul><h3>Life Science Services Segment</h3><ul><li>Net Revenues: $31,630 for the three months ended September 30, 2025, with no comparable revenue in 2024 as the segment began with the acquisition of Vector on September 19, 2025.</li><li>Segment Loss: $3,504 for the three months ended September 30, 2025.</li></ul><h3>Labs Segment</h3><ul><li>Net Revenues: $8,242 for the three months ended September 30, 2025, compared to $8,752 for the same period in 2024, a decrease of $510.</li><li>Segment Loss: $70,027 for the three months ended September 30, 2025, compared to $381,405 for the same period in 2024, a decrease of $311,378.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to grow its healthcare segment by acquisition and investment in new operations in targeted areas. For the Labs segment, the focus is on commercializing epigenetic biomarker technology and developing new tools and partnerships to advance research.</li><li>Non-Core Business: The company is considering a spin-off of its FOXO Labs, Inc. subsidiary to focus on the development of its epigenetics business.</li></ul>

FOXO TECHNOLOGIES INC | 10-Q: FY2025 Q3 Revenue: USD 3.548 M